{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:11:10Z","timestamp":1767849070757,"version":"3.49.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,12,22]],"date-time":"2012-12-22T00:00:00Z","timestamp":1356134400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Pharmacokinet Pharmacodyn"],"published-print":{"date-parts":[[2013,2]]},"DOI":"10.1007\/s10928-012-9287-8","type":"journal-article","created":{"date-parts":[[2012,12,21]],"date-time":"2012-12-21T08:38:40Z","timestamp":1356079120000},"page":"67-80","source":"Crossref","is-referenced-by-count":23,"title":["Assessment of glycemic response to an oral glucokinase activator in a proof of concept study: application of a semi-mechanistic, integrated glucose-insulin-glucagon model"],"prefix":"10.1007","volume":"40","author":[{"given":"Karen B.","family":"Schneck","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mats O.","family":"Karlsson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikram P.","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,12,22]]},"reference":[{"issue":"10","key":"9287_CR1","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1177\/0091270007302168","volume":"47","author":"PM Jauslin","year":"2007","unstructured":"Jauslin PM, Silber HE, Frey N, Gieschke R, Simonsson US, Jorga K, Karlsson MO (2007) An integrated glucose-insulin model to describe oral glucose tolerance test data in type 2 diabetics. J Clin Pharmacol 47(10):1244\u20131255","journal-title":"J Clin Pharmacol"},{"issue":"9","key":"9287_CR2","doi-asserted-by":"crossref","first-page":"1159","DOI":"10.1177\/0091270007304457","volume":"47","author":"HE Silber","year":"2007","unstructured":"Silber HE, Jauslin PM, Frey N, Gieschke R, Simonsson US, Karlsson MO (2007) An integrated model for glucose and insulin regulation in healthy volunteers and type 2 diabetic patients following intravenous glucose provocations. J Clin Pharmacol 47(9):1159\u20131171","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9287_CR3","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/j.1742-7843.2009.00510.x","volume":"106","author":"HE Silber","year":"2010","unstructured":"Silber HE, Jauslin PM, Frey N, Karlsson MO (2010) An integrated model for the glucose-insulin system. Basic Clin Pharmacol Toxicol 106(3):189\u2013194","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"9287_CR4","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1177\/0091270010362536","volume":"51","author":"PM Jauslin","year":"2011","unstructured":"Jauslin PM, Frey N, Karlsson MO (2011) Modeling of 24-hour glucose and insulin profiles of patients with type 2 diabetes. J Clin Pharmacol 51(2):153\u2013164","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"9287_CR5","doi-asserted-by":"crossref","first-page":"1861","DOI":"10.1177\/0091270011422231","volume":"52","author":"PM Jauslin","year":"2011","unstructured":"Jauslin PM, Karlsson MO, Frey N (2011) Identification of the mechanism of action of a glucokinase activator from oral glucose tolerance test data in type 2 diabetic patients based on an integrated glucose-insulin model. J Clin Pharmacol 52(12):1861\u20131871","journal-title":"J Clin Pharmacol"},{"issue":"3","key":"9287_CR6","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/s10928-006-9008-2","volume":"33","author":"W Winter de","year":"2006","unstructured":"de Winter W, DeJongh J, Post T, Ploeger B, Urquhart R, Moules I, Eckland D, Danhof M (2006) A mechanism-based disease progression model for comparison of long-term effects of pioglitazone, metformin and gliclazide on disease processes underlying Type 2 Diabetes Mellitus. J Pharmacokinet Pharmacodyn 33(3):313\u2013343","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"7","key":"9287_CR7","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2165\/00003088-200847070-00001","volume":"47","author":"CB Landersdorfer","year":"2008","unstructured":"Landersdorfer CB, Jusko WJ (2008) Pharmacokinetic\/pharmacodynamic modelling in diabetes mellitus. Clin Pharmacokinet 47(7):417\u2013448","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"9287_CR8","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1124\/dmd.111.042291","volume":"40","author":"W Gao","year":"2012","unstructured":"Gao W, Jusko WJ (2012) Target-mediated pharmacokinetic and pharmacodynamic model of exendin-4 in rats, monkeys and man. Drug Metab Dispos 40(5):990\u2013997","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"9287_CR9","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.2011.04109.x","volume":"73","author":"CB Landersdorfer","year":"2012","unstructured":"Landersdorfer CB, He YL, Jusko WJ (2012) Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes. Br J Clin Pharmacol 73(3):373\u2013390","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"9287_CR10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1111\/j.1742-7843.2009.00456.x","volume":"106","author":"SG Dahl","year":"2010","unstructured":"Dahl SG, Aarons L, Gundert-Remy U, Karlsson MO, Schneider YJ, Steimer JL, Troconiz IF (2010) Incorporating physiological and biochemical mechanisms into pharmacokinetic-pharmacodynamic models: a conceptual framework. Basic Clin Pharmacol Toxicol 106(1):2\u201312","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"5","key":"9287_CR11","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrd2850","volume":"8","author":"FM Matschinsky","year":"2009","unstructured":"Matschinsky FM (2009) Assessing the potential of glucokinase activators in diabetes therapy. Nat Rev Drug Discov 8(5):399\u2013416","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"9287_CR12","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1023\/B:JOPA.0000012998.04442.1f","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheiner LB (2003) Simultaneous vs. sequential analysis for population PK\/PD data I: best-case performance. J Pharmacokinet Pharmacodyn 30(6):387\u2013404","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"6","key":"9287_CR13","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1023\/B:JOPA.0000012999.36063.4e","volume":"30","author":"L Zhang","year":"2003","unstructured":"Zhang L, Beal SL, Sheinerz LB (2003) Simultaneous vs. sequential analysis for population PK\/PD data II: robustness of methods. J Pharmacokinet Pharmacodyn 30(6):405\u2013416","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"3","key":"9287_CR14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00676.x","volume":"45","author":"A Sharma","year":"1998","unstructured":"Sharma A, Jusko WJ (1998) Characteristics of indirect pharmacodynamic models and applications to clinical drug responses. Br J Clin Pharmacol 45(3):229\u2013239","journal-title":"Br J Clin Pharmacol"},{"key":"9287_CR15","unstructured":"Bauer R (2011) NONMEM User\u2019s guide, introduction to NONMEM 7.2.0. ICON Development solutions, Ellicott City, MD"},{"issue":"2","key":"9287_CR16","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1023\/A:1011555016423","volume":"28","author":"Y Yano","year":"2001","unstructured":"Yano Y, Beal SL, Sheiner LB (2001) Evaluating pharmacokinetic\/pharmacodynamic models using the posterior predictive check. J Pharmacokinet Pharmacodyn 28(2):171\u2013192","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"5","key":"9287_CR17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.2337\/diabetes.48.5.1198","volume":"48","author":"AD Cherrington","year":"1999","unstructured":"Cherrington AD (1999) Banting Lecture, 1997.Control of glucose uptake and release by the liver in vivo. Diabetes 48(5):1198\u20131214","journal-title":"Diabetes"},{"issue":"Suppl 1","key":"9287_CR18","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1463-1326.2011.01454.x","volume":"13","author":"CJ Ramnanan","year":"2011","unstructured":"Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD (2011) Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes Metab 13(Suppl 1):118\u2013125","journal-title":"Diabetes Obes Metab"},{"issue":"3","key":"9287_CR19","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1172\/JCI2415","volume":"102","author":"C Meyer","year":"1998","unstructured":"Meyer C, Stumvoll M, Nadkarni V, Dostou J, Mitrakou A, Gerich J (1998) Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 102(3):619\u2013624","journal-title":"J Clin Invest"},{"issue":"6","key":"9287_CR20","doi-asserted-by":"crossref","first-page":"E1049","DOI":"10.1152\/ajpendo.00041.2004","volume":"287","author":"C Meyer","year":"2004","unstructured":"Meyer C, Woerle HJ, Dostou JM, Welle SL, Gerich JE (2004) Abnormal renal, hepatic, and muscle glucose metabolism following glucose ingestion in type 2 diabetes. Am J Physiol Endocrinol Metab 287(6):E1049\u2013E1056","journal-title":"Am J Physiol Endocrinol Metab"},{"issue":"Suppl 1","key":"9287_CR21","first-page":"A272","volume":"60","author":"JM Bue-Valleskey","year":"2011","unstructured":"Bue-Valleskey JM, Schneck KB, Sinha VP, Wondmagegnehu ET, Kapitza C, Miller JW (2011) LY2599506, a novel glucokinase activator (GKA), improves fasting and postprandial glucose in patients wtih type 2 diabetes mellitus (T2DM) [abstract]. Diabetes 60(Suppl 1):A272","journal-title":"Diabetes"},{"key":"9287_CR22","unstructured":"Bue-Valleskey JM, Schneck KB, Sinha VP, Wondmagegnehu ET, Kapitza C, Miller JW (2011) LY2599506, a novel glucokinase activator (GKA), improves fasting and postprandial glucose in patients wtih Type 2 diabetes mellitus. In: 47th EASD Annual Meeting, Lisbon, 12\u201316 September 2011. European Association for the study of diabetes"},{"issue":"Suppl 1","key":"9287_CR23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1463-1326.2011.01450.x","volume":"13","author":"JN Walker","year":"2011","unstructured":"Walker JN, Ramracheya R, Zhang Q, Johnson PR, Braun M, Rorsman P (2011) Regulation of glucagon secretion by glucose: paracrine, intrinsic or both? Diabetes Obes Metab 13(Suppl 1):95\u2013105","journal-title":"Diabetes Obes Metab"},{"key":"9287_CR24","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1210\/rp.56.1.195","volume":"56","author":"C Postic","year":"2001","unstructured":"Postic C, Shiota M, Magnuson MA (2001) Cell-specific roles of glucokinase in glucose homeostasis. Recent Prog Horm Res 56:195\u2013217","journal-title":"Recent Prog Horm Res"},{"issue":"1","key":"9287_CR25","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1074\/jbc.274.1.305","volume":"274","author":"C Postic","year":"1999","unstructured":"Postic C, Shiota M, Niswender KD, Jetton TL, Chen Y, Moates JM, Shelton KD, Lindner J, Cherrington AD, Magnuson MA (1999) Dual roles for glucokinase in glucose homeostasis as determined by liver and pancreatic beta cell-specific gene knock-outs using Cre recombinase. J Biol Chem 274(1):305\u2013315","journal-title":"J Biol Chem"},{"key":"9287_CR26","unstructured":"Bauer R (2008) S-ADAPT\/MCPEM User\u2019s Guide (version 1.56). Berkeley, CA"},{"issue":"2","key":"9287_CR27","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1038\/clpt.2008.2","volume":"84","author":"B Hamren","year":"2008","unstructured":"Hamren B, Bjork E, Sunzel M, Karlsson M (2008) Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. Clin Pharmacol Ther 84(2):228\u2013235","journal-title":"Clin Pharmacol Ther"}],"container-title":["Journal of Pharmacokinetics and Pharmacodynamics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-012-9287-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10928-012-9287-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10928-012-9287-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,3]],"date-time":"2024-05-03T21:56:09Z","timestamp":1714773369000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10928-012-9287-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,12,22]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,2]]}},"alternative-id":["9287"],"URL":"https:\/\/doi.org\/10.1007\/s10928-012-9287-8","relation":{},"ISSN":["1567-567X","1573-8744"],"issn-type":[{"value":"1567-567X","type":"print"},{"value":"1573-8744","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,12,22]]}}}